Cardinal Health stock: Mizuho lifts target to USD 280 pre-market
Published on 10/22/2026 at 08:14 | Editorial responsibility: Rafael MĂĽller, Editor-in-Chief AD HOC NEWSMizuho updates its valuation view
- Mizuho analysts raised Cardinal Health’s target to USD 280 from USD 250 on October 21, 2026.
- Cardinal Health is scheduled to report fiscal first-quarter results on November 5, 2026.
- Cardinal Health stock trades pre-market at EUR 229.30 at 8:10 a.m. CEST at Lang & Schwarz on October 22, 2026.
Mizuho analysts raised their price target for Cardinal Health to USD 280 from USD 250 and maintained an outperform rating, according to an October 21, 2026 report by Investor’s Business Daily. Cardinal Health stock trades pre-market at EUR 229.30 at 8:10 a.m. CEST at Lang & Schwarz on October 22, 2026.
Analyst target raised
The report said the target change formed part of an earnings preview for the pharmaceuticals distributor. Mizuho kept its outperform rating, while the article identified improving U.S. prescription growth as part of the analysts’ assessment. The report did not identify Cardinal Health as the actor behind the target change; the action was attributed to Mizuho analysts. Investor’s Business Daily carried the account.
Ahead of the Xetra open
The bid was EUR 227.80 and the ask was EUR 230.80, a spread of 1.31 percent. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Cardinal Health stock.
The group and its calendar
Cardinal Health distributes pharmaceuticals to pharmacies and other destinations and manufactures and distributes medical and laboratory products, according to Investor’s Business Daily. The same October 21 report said the company will announce fiscal first-quarter results on the morning of November 5, 2026. Market context: Market report S&P 500.
